A Randomized Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Noninfectious Uveitis

• Published in: Ophthalmology (Rochester, Minn.) Vol. 121; no. 10; pp. 1863 - 1870
• Main Authors: Rathinam, Sivakumar R., MD, PhD, Babu, Manohar, MD, Thundikandy, Radhika, MD, Kanakath, Anuradha, MD, Nardone, Natalie, PhD, Esterberg, Elizabeth, MS, Lee, Salena M., OD, Enanoria, Wayne T.A., PhD, MPH, Porco, Travis C., PhD, MPH, Browne, Erica N., MS, Weinrib, Rachel, MPH, Acharya, Nisha R., MD, MS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2014
• Subjects: Administration, Oral; Adult; Female; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Macular Edema - drug therapy; Male; Methotrexate - adverse effects; Methotrexate - therapeutic use; Middle Aged; Mycophenolic Acid - adverse effects; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; Ophthalmology; Uveitis - drug therapy; Visual Acuity; Young Adult
• ISSN: 0161-6420; 1549-4713
• DOI: 10.1016/j.ophtha.2014.04.023

Objective To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Design Multicenter, block-randomized, observer-masked clinical trial. Participants Eighty patients with noninfectious intermediate, posterior, or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai and Coimbatore, India. Intervention Patients were randomized to receive 25 mg weekly oral methotrexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 months. Oral prednisone and topical corticosteroids were tapered. Main Outcome Measures Masked examiners assessed the primary outcome of treatment success, defined by achieving the following at 5 and 6 months: (1) ≤0.5+ anterior chamber cells, ≤0.5+ vitreous cells, ≤0.5+ vitreous haze and no active retinal/choroidal lesions in both eyes, (2) ≤10 mg of prednisone and ≤2 drops of prednisolone acetate 1% a day, and (3) no declaration of treatment failure because of intolerability or safety. Additional outcomes included time to sustained corticosteroid-sparing control of inflammation, change in best spectacle-corrected visual acuity, resolution of macular edema, adverse events, subgroup analysis by anatomic location, and medication adherence. Results Forty-one patients were randomized to methotrexate and 39 to mycophenolate mofetil. A total of 67 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcome. Sixty-nine percent of patients achieved treatment success with methotrexate and 47% with mycophenolate mofetil ( P  = 0.09). Treatment failure from adverse events or tolerability was not different by treatment arm ( P  = 0.99). There were no differences between treatment groups in time to corticosteroid-sparing control of inflammation ( P  = 0.44), change in best spectacle-corrected visual acuity ( P  = 0.68), or resolution of macular edema ( P  = 0.31). Conclusions There was no statistically significant difference in corticosteroid-sparing control of inflammation between patients receiving methotrexate or mycophenolate mofetil. However, there was a 22% difference in treatment success favoring methotrexate.